OCEAN, said Albert, provides important risk-benefit data that doctors can now use in discussions with their patients. For ...

NEW ORLEANS, LA—Among patients with atrial fibrillation (AF) undergoing PCI, 1 month of dual therapy with a direct oral ...

The drug, given as a weekly subcutaneous injection, reduced both triglycerides and liver fat in the phase II trial.

The approach is “very exciting,” but one expert says a lot more research is needed, especially around safety, before clinical ...

It’s the first study to show a PCSK9 inhibitor can reduce major events in high-risk patients who haven’t yet had one.

Follow-up over 10 years may show different patterns, and experts predict DCBs will likely be useful in certain populations.

The small-profile device expands to capture clots like large-bore systems while offering good reduction in RV/LV ratio at 48 ...

Experts gathered at the TCT MedTech Innovation Forum to discuss successes, failures, barriers, and solutions in healthcare.

The single-arm INVEST-CTO study showed high procedural success with a two-part intervention, but questions remain.

One question, in light of FREEDOM, is how well new DES compare with CABG in patients with diabetes and multivessel disease.

A total of 399 patients underwent TEE and were taking their assigned treatment at 60 days follow-up.

The NyokAssist device, from China, had few adverse outcomes by 30 days. More devices—and more trials—are on the way.